Author:
Kondo Masahiro,Naiki Taku,Hotta Yuji,Yamamoto Yuko,Sugiyama Yosuke,Yasui Takahiro,Kimura Kazunori
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology (nursing)
Reference15 articles.
1. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer Version 2. 2018. Available from
www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
. Accessed 15 May 2018.
2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77.
3. Motzer RJ, Niedzwiecki D, Isaacs M, Menendez-Botet C, Tong WP, Flombaum C, et al. Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol. 1990;27:234–8.
4. Wada T, Fukuda T, Kawanishi M, Tasaka R, Imai K, Yamauchi M, et al. Pharmacokinetic analyses of carboplatin in a patient with cancer of the fallopian tubes undergoing hemodialysis: a case report. Biomed Rep. 2016;5:199–202.
5. Oguri T, Shimokata T, Ito I, Yasuda Y, Sassa N, Nishiyama M, et al. Extension of the Calvert formula to patients with severe renal insufficiency. Cancer Chemother Pharmacol. 2015;76:53–9.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Carboplatin/gemcitabine;Reactions Weekly;2019-01